Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne Muscular Dystrophy,” on Wednesday, November 7, 2018 at 1:00pm ET.

Speakers Include:
Joanne Donovan, M.D., Ph.D., Chief Medical Officer, Catabasis Pharmaceuticals
Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Dr. Donovan will discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy (DMD), which is enrolling boys ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months. Topics will include discussion of the PolarisDMD clinical trial, endpoints, inclusion and exclusion criteria, and information on edasalonexent, including previous clinical results that showed preserved muscle function in boys affected by Duchenne with edasalonexent treatment compared to the off-treatment period as well as significantly improved biomarkers.

The webinar can be accessed by visiting http://bit.ly/2Puskwr.

About Edasalonexent
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential new standard of care for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, which is a key link between loss of dystrophin and disease progression. NF-kB has a fundamental role in skeletal and cardiac muscle disease in DMD. Catabasis is currently enrolling the single global Phase 3 PolarisDMD trial to evaluate the efficacy and safety of edasalonexent for registration purposes. In the clinic, we observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers. Edasalonexent continues to be dosed in an open-label extension of the MoveDMD Phase 2 clinical trial. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit www.catabasis.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005024/en/